In a multiplex PCR-based respiratory syndromic panel for a ventilated patient with hospital-acquired pneumonia, both Klebsiella pneumoniae and a CRKP-associated KPC resistance gene are detected. What is the most appropriate interpretation and immediate clinical action?

• A Syndromic PCR confirms presence of the resistance gene in the sample; send sample for culture, antimicrobial susceptibility testing (AST), and MIC determination before finalising therapy ✓
• B Positive syndromic PCR is diagnostic; initiate colistin-based combination therapy immediately
• C PCR detects dead bacteria; the result is not clinically relevant and standard first-line therapy should continue
• D The KPC gene PCR signal confirms bacteraemia; start meropenem double-dose therapy immediately

Explanation

Syndromic PCR/molecular panels (e.g., BioFire FilmArray BCID, respiratory panel) detect nucleic acid targets from the clinical sample rapidly (1–2 hours). Detection of both a pathogen and resistance gene (e.g., KPC blaKPC gene) is highly informative for initial antimicrobial stewardship decisions. However, PCR cannot determine phenotypic susceptibility (MIC), quantify bacterial load, or differentiate whether resistance gene is expressed at clinically significant levels. The standard of care requires parallel culture and formal AST to guide definitive therapy — colistin MIC, ceftazidime-avibactam MIC, and combination susceptibility testing. Empirical modification (de-escalating carbapenems, adding ceftazidime-avibactam) can be guided by PCR pending culture confirmation.

Reference: Ananthanarayan & Paniker's Textbook of Microbiology, 11th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.